The model developed herein was used to predict the TG-2 inhibitor activity and other potential therapeutic agents for CD such as antibodies against IFN-γ and IL-15, gluten peptide-related agents that arrest activation of APCs (DQ2 blocking peptide analogues) [52-55], and gluten peptide-related agents that repress IEC activation (permeability inhibitors) [56]. Here, TOR1A is linked to Cowden disease.